Androgen receptor as a therapeutic target for androgen independent prostate cancer

Nima Sharifi, William L. Farrar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

Original languageEnglish (US)
Pages (from-to)166-170
Number of pages5
JournalAmerican Journal of Therapeutics
Volume13
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Androgen Receptors
Androgens
Prostatic Neoplasms
Therapeutics
Second Primary Neoplasms
Testosterone
Cause of Death
Growth
Neoplasms

Keywords

  • Androgen receptors
  • Genes
  • Medical oncology
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

Androgen receptor as a therapeutic target for androgen independent prostate cancer. / Sharifi, Nima; Farrar, William L.

In: American Journal of Therapeutics, Vol. 13, No. 2, 03.2006, p. 166-170.

Research output: Contribution to journalArticle

Sharifi, Nima ; Farrar, William L. / Androgen receptor as a therapeutic target for androgen independent prostate cancer. In: American Journal of Therapeutics. 2006 ; Vol. 13, No. 2. pp. 166-170.
@article{6f6c17123bcd4a68beb19c49e373611b,
title = "Androgen receptor as a therapeutic target for androgen independent prostate cancer",
abstract = "Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.",
keywords = "Androgen receptors, Genes, Medical oncology, Prostatic neoplasms",
author = "Nima Sharifi and Farrar, {William L.}",
year = "2006",
month = "3",
doi = "10.1097/00045391-200603000-00013",
language = "English (US)",
volume = "13",
pages = "166--170",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Androgen receptor as a therapeutic target for androgen independent prostate cancer

AU - Sharifi, Nima

AU - Farrar, William L.

PY - 2006/3

Y1 - 2006/3

N2 - Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

AB - Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

KW - Androgen receptors

KW - Genes

KW - Medical oncology

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=33646576828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646576828&partnerID=8YFLogxK

U2 - 10.1097/00045391-200603000-00013

DO - 10.1097/00045391-200603000-00013

M3 - Article

C2 - 16645434

AN - SCOPUS:33646576828

VL - 13

SP - 166

EP - 170

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -